You are here » Home » Companies » Company Overview » Ambalal Sarabhai Enterprises Ltd

Ambalal Sarabhai Enterprises Ltd.

BSE: 500009	Sector: Health care
NSE: AMBASARABH	ISIN Code: INE432A01017

BSE 10:18 | 30 Jan

24.40

-0.15
(-0.61%)

OPEN

24.95

HIGH

24.95

LOW

24.20

NSE 05:30 | 01 Jan

Ambalal Sarabhai Enterprises Ltd

Add to Watchlist | Add to Portfolio

OPEN	24.95
PREVIOUS CLOSE	24.55
VOLUME	4036
52-Week high	44.60
52-Week low	24.20
P/E	37.54
Mkt Cap.(Rs cr)	187
Buy Price	24.40
Buy Qty	572.00
Sell Price	24.50
Sell Qty	140.00

OPEN	24.95
CLOSE	24.55
VOLUME	4036
52-Week high	44.60
52-Week low	24.20
P/E	37.54
Mkt Cap.(Rs cr)	187
Buy Price	24.40
Buy Qty	572.00
Sell Price	24.50
Sell Qty	140.00

Ambalal Sarabhai Enterprises Ltd. (AMBASARABH) - News Sector

Enzene Biosciences raises $50 million, aims to expand into global markets

12.22 am | 30 Jan 2023 | Business Standard

Enzene said it has built a highly experienced 400-person team under the leadership of Dr. Himanshu Gadgil, CEO at Enzene Biosciences Ltd
Flows to Indian equities are at risk as investors eye China: Chris Wood

10.55 pm | 27 Jan 2023 | Business Standard

He believes India remains the best long-term equity story in Asian and the emerging market (EM) context
Torrent Pharma Q3 PAT up 14% to Rs 249 crore riding on India, Brazil

10.45 pm | 25 Jan 2023 | Business Standard

Torrent Pharma's revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71...
DRL posts strong 77% profit growth to Rs 1,247 cr riding on US, Russia

6.59 pm | 25 Jan 2023 | Business Standard

Firm says sustained focus on improving productivity has also helped boost profits; DRL is now bullish on its biosimilars and hopes to start filing for...
Torrent Pharma Q3 net profit up 14% to Rs 283 cr; interim dividend declared

6.26 pm | 25 Jan 2023 | Press Trust of India

Torrent Pharma on Wednesday said its consolidated net profit increased by 14 per cent to Rs 283 crore in the third quarter ended December 31, 2022. T...
Cipla Q3 net up 10% to Rs 801 cr, posts highest ever quarterly sales in US

5.44 pm | 25 Jan 2023 | Business Standard

Revenue up 6% to Rs 5,810 cr; firm expects US FDA audit at Goa unit
Lupin Digital launches Lyfe, a 24x7 monitoring ecosystem for heart patients

8.35 pm | 24 Jan 2023 | Business Standard

Company aims to onboard one million patients the platform, which aims to help them improve heart health through doctor-connected online and offline mo...
Sun Pharma to acquire US-based Concert Pharmaceuticals for $576 million

10.09 pm | 19 Jan 2023 | Business Standard

Deal size could expand to $827 mn if additional milestone-based payments are made
Cipla launches diagnostic device, says it will provide results in minutes

11.55 am | 18 Jan 2023 | Business Standard

Cippoint offers parameters to test for cardiac markers, diabetes, infectious diseases, fertility
Lupin gets USFDA tentative nod for generic drugs to treat HIV infection

12.14 am | 17 Jan 2023 | Press Trust of India

Pharmaceutical firm Lupin on Monday said it has received tentative approval from the US health regulator to market its generic version of Dolutegravir...
Breather for Natco in Novartis cardiac drug case from Delhi High Court

9.33 pm | 15 Jan 2023 | Business Standard

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week
Breather for Natco in Novartis cardiac drug case from Delhi High Court

9.33 pm | 15 Jan 2023 | Business Standard

May open floodgates for Indian drugmakers to launch the generic version of the drug as early as next week
RIL, Dr Reddy's Labs: 5 Nifty500 stocks cross 200-DMA, defying weak trend

11.48 am | 10 Jan 2023 | Business Standard

Following a strong close over the 200-DMA set at Rs 2,559, the chart structure of Reliance Industries reveals a "Double Bottom" breakout
Mehul Kothari recommends to buy Laurus Labs, RateGain Travel Technologies

7.44 am | 10 Jan 2023 | Business Standard

According to the technical analyst from Anand Rathi, Laurus Labs can rally to Rs 400; while RateGain can jump to Rs 330.
F&O Call: Nandish Shah recommends to long Glenmark Pharma futures

8.02 am | 6 Jan 2023 | Business Standard

The derivative analyst from HDFC Securities expects Glenmark Pharma January futues to test Rs 450 on the upside.
Pfizer announces 12-week paternity leave policy for its employees

9.09 pm | 5 Jan 2023 | Business Standard

The policy that came into effect on January 1, 2023, gives biological and adoptive fathers the option to take leaves in up to four tranches
Granules forges strategic partnership with Greenko ZeroC for Kakinada plant

3.24 pm | 3 Jan 2023 | Business Standard

Under the collaboration, Greenko ZeroC will be supplying carbon free energy and enable green hydrogen along with its various chemical derivatives
Stocks to Watch: Elin Electronics, Cipla, Eicher Motors, RIL, Banks, Pharma

8.17 am | 30 Dec 2022 | Business Standard

Stocks to Watch: Elin Electronics to debut today, the stock is likely to list on a quiet note.
Stocks to Watch: NTPC, LIC Housing, Alembic Pharma, SIS, Gail, Puravankara

8.03 am | 27 Dec 2022 | Business Standard

Stocks to Watch: In the F&O space, Punjab National Bank (PNB) is the only stock in ban period on Tuesday.
Alembic Pharma gets USFDA nod for generic drug to treat breast cancer

5.30 pm | 26 Dec 2022 | Press Trust of India

Alembic Pharmaceuticals on Monday said it has received final approval from the US health regulator for its generic Fulvestrant injection used in treat...